|
Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial
RECRUITINGN/ASponsored by Yonsei University
Actively Recruiting
PhaseN/A
SponsorYonsei University
Started2022-07-26
Est. completion2028-07-10
Eligibility
Age19 Years – 84 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05320926
Summary
Previous randomized clinical trials have deomonstrated the efficacy and safety of short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), however, the single antiplatelet agent to be maintained after short-term DAPT was different. Therefore, which antiplatelet agent to be maintained after short-term DAPT needs further invstigations.
Eligibility
Age: 19 Years – 84 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Patients ≥19 years 2. Patients who received new generation zotarolimus-eluting Onyx stents implantation for treating ischemic heart disease 3. Provision of informed consent Exclusion Criteria: 1. Age ≥ 85 years 2. Acute myocardial infarction 2\. Left main bifurcation requiring 2-stent technique 3. Pregnant women or women with potential childbearing 4. Life expectancy \< 1 year 5. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator 6. Inability to understand or read the informed consent
Conditions2
Heart DiseaseIschemic Heart Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorYonsei University
Started2022-07-26
Est. completion2028-07-10
Eligibility
Age19 Years – 84 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05320926